Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P F Halloran

Showing results (51-60 of 237) with videos related to

Pageof 24
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 26, 2006
Lies, damn lies, and statistics: the perils of the P valueP F Halloran, J Reeve, B Kaplan
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 8, 2006
Histologic findings from positive crossmatch or ABO-incompatible renal allografts: accomodation or chronic allograft injury?B Sis, B Kaplan, P F Halloran
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 13, 2007
SWOT analysis of Banff: strengths, weaknesses, opportunities and threats of the international Banff consensus process and classification system for renal allograft pathologyM Mengel, B Sis, P F Halloran
Transplantation|April 1, 1986
The regulation of expression of major histocompatibility complex productsP F Halloran, A Wadgymar, P Autenried
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 8, 2008
Open letter to the FDA: new drug trials must be relevantF Vincenti, G Klintmalm, P F Halloran
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 23, 2016
Hyalinosis Lesions in Renal Transplant Biopsies: Time-Dependent Complexity of InterpretationG Einecke, J Reeve, P F Halloran
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 3, 2011
Histological characteristics of calcineurin inhibitor toxicity--there is no such thing as specificity!M Mengel, M Mihatsch, P F Halloran
Transplantation Proceedings|September 2, 1998
Calcineurin and the biological effect of cyclosporine and tacrolimusP F Halloran, L Kung, J Noujaim
Clinical Nephrology|October 29, 1997
Reply to Shoker et alK Trpkov, K Solez, P F Halloran
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 11, 2011
Managing risk in developing transplant immunosuppressive agents: the new regulatory environmentS Gabardi, P F Halloran, J Friedewald
Pageof 24

Showing results (51-60 of 237) with videos related to

Sort By:
Pageof 24
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 26, 2006
Lies, damn lies, and statistics: the perils of the P valueP F Halloran, J Reeve, B Kaplan
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 8, 2006
Histologic findings from positive crossmatch or ABO-incompatible renal allografts: accomodation or chronic allograft injury?B Sis, B Kaplan, P F Halloran
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 13, 2007
SWOT analysis of Banff: strengths, weaknesses, opportunities and threats of the international Banff consensus process and classification system for renal allograft pathologyM Mengel, B Sis, P F Halloran
Transplantation|April 1, 1986
The regulation of expression of major histocompatibility complex productsP F Halloran, A Wadgymar, P Autenried
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 8, 2008
Open letter to the FDA: new drug trials must be relevantF Vincenti, G Klintmalm, P F Halloran
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 23, 2016
Hyalinosis Lesions in Renal Transplant Biopsies: Time-Dependent Complexity of InterpretationG Einecke, J Reeve, P F Halloran
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 3, 2011
Histological characteristics of calcineurin inhibitor toxicity--there is no such thing as specificity!M Mengel, M Mihatsch, P F Halloran
Transplantation Proceedings|September 2, 1998
Calcineurin and the biological effect of cyclosporine and tacrolimusP F Halloran, L Kung, J Noujaim
Clinical Nephrology|October 29, 1997
Reply to Shoker et alK Trpkov, K Solez, P F Halloran
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 11, 2011
Managing risk in developing transplant immunosuppressive agents: the new regulatory environmentS Gabardi, P F Halloran, J Friedewald
Pageof 24